Eva Pella

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read the Review Article “GLP-1 Receptor Agonists” by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, from @tuftsmedschool and the Maine Medical Center Institute for Research: nejm.org/doi/full/10.10…

Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: biological challenges and clinical implications Excellent review @NDTsocial academic.oup.com/ndt/article/41… I learned three important facts

🧵 1/9 As Nephrology Dialysis Transplantation @NDTsocial celebrates 40 years 🎉, a new editorial ✨ highlights how biological sex shapes CV benefits of exercise in CKD. @VanAmaryllis @olgabalafa @anagarcp #WERA Read the full article at 🔗academic.oup.com/ndt/advance-ar… Read the thread for a sneak peek 👇👇 👇

Can AI read an ECG like a cardiologist - from just an image? We built ECG-GPT, a vision-text transformer that generates complete diagnostic reports directly from photos of 12-lead ECGs Now out in @ESC_Journals #EHJDigitalHealth Kudos to @aakhunte & @Veer_Sangha_ for leading this @cards_lab 🧵

In this Fellows First article in #ASNKidneyNews, nephrology fellow Harsha Adnani outlines ten tips for building a sustainable career from the start. Read the tips here: kidney.pub/KN1803-06

👉🏻 Check out this month snapshot summary about CAKUT disease in adult patients doi.org/10.1093/ndt/gf… ✍️Charlotte Hammett is the YNP author Post prepared by @jt_nephrology @NDTsocial @ERAkidney

Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis bit.ly/44IMgkk @winkeldoc @Khairallah_P @MingyueHe3 @MontezRath @taraichang

What's New in Membranous Nephropathy and How to Incorporate New Antigen Discoveries into Clinical Practice? REVIEW by @LadanZand @fervenzafernan1 @SethiRenalPath bit.ly/3J9d1qO

QT-prolonging medications: prevalence of use and associated risks in CKD doi.org/10.1093/ndt/gf…

Want to learn more about Europe’s key data source for kidney replacement therapy (KRT)? The ERA Registry Annual Report provides a comprehensive view of KRT across Europe, with insights at both European and national levels 🌍 Inside the report you’ll find: 📊 Data on incidence, prevalence, patient characteristics and outcomes 📈 The possibility to benchmark across countries ⚖️ Insights to support fair resource allocation and policy decisions Swipe to discover some key insights from the 2023 report! #ERARegistry #KidneyHealth #KRT #ERA #KidneyReplacementTherapy #KidneyTransplant #Kidneys #Dialysis

✨ Today, we celebrate the women who are making an impact and the many more who will. ⚡For International Women’s Day, we asked the women in leadership at ERA a simple but powerful question: “What message would you like to share with young women who want to make a difference?” 🫶 Each message is a reminder that making a difference starts with courage, curiosity, and the willingness to take the first step.

Apply to be a board member of the YNP! 👇🏻

Targeting HIF2-PTHrP axis in kidney cancer: a paradigm shift in therapy? 📖doi.org/10.1093/ckj/sf…

🏃 #PhysicalActivity is essential for preventing #obesity and improving mental wellbeing. Increasing physical activity protects children and adults from obesity – a risk factor for #NCDs. bit.ly/44Wgy2f #WorldObesityDay

📊 JAMA Guide to Statistics and Methods: The Hochberg procedure is a multiplicity correction used in clinical trials to control the familywise error rate when comparing multiple end points. Learn more: ja.ma/4ctfEjw

What if this (or VO2AT) is the missing link to quantify physical activity and integrate it into risk equations? 🏃‍♂️ #CPET #Cardiorespiratory_fitness #Physical_activity #Exercise VO2Peak: The Emerging Endpoint For Cardiovascular Outcome... : Kidney360 journals.lww.com/kidney360/abst…

How to interpret the number needed to treat for clinicians 🔓doi.org/10.1093/ndt/gf… @EraRegistry

BELIEVE it or not… this obesity trial suggests we may finally separate fat loss from muscle loss. In the BELIEVE trial (Nature Medicine): 🔹 Semaglutide alone → ~15.7% weight loss 🔹 Combination therapy → ~22% weight loss (~24 kg) 🔹 Total body fat ↓ ~46% 🔹 Visceral fat ↓ ~58% 🔹 Lean muscle largely preserved For decades, weight loss meant losing muscle + metabolic reserve. This approach targets appetite AND muscle biology simultaneously. If confirmed in outcomes trials, this could reshape how we think about: ❤️ cardiometabolic disease 💪 sarcopenic obesity 🫀 surgical risk & frailty We may be moving from weight loss → body composition medicine. #Obesity #CardioMetabolic #GLP1 #Semaglutide #Longevity #HeartHealth #PreventiveMedicine #NatureMedicine #MedTwitter #Cardiology #Endocrinology #DigitalHealth #FutureOfMedicine #HealthyAging #PrecisionMedicine

Now open access in @NDTsocial The updated global burden of CKD: one death every 20 seconds 🧐The global and European CKD burden call for novel strategies that expand beyond screening, early diagnosis and treatment of CKD ▶️academic.oup.com/ndt/article/do…

Microscopic hematuria in IgA nephropathy: a biomarker of disease activity Jürgen Floege , Fernando C Fervenza , Rosanna Coppo @CKJsocial academic.oup.com/ckj/article/19…